0001437749-24-038124 | 10-Q | XBRL Viewer | Streamline Health Solutions INC

Fair Value, Inputs, Level 1 [Member]

$ 1,794,000

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 3 [Member]

$ 1,794,000

[1]

On March 27, 2024, the Company issued the shares of its common stock owed as part of the acquisition earnout liability related to the acquisition of Avelead Consulting, LLC (“Avelead”). The remaining obligation related to the acquisition earnout liability is to be settled in cash (refer to Note 3 – Business Combinations for more information). At that time, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was removed from the hierarchy. As of that date, the Company recorded a valuation adjustment of $159,000 using the value of the shares issued adjusted for a discount for lack of marketability. As of April 30, 2024, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was transferred out. See the table below for the roll-forward of values including the amount transitioned out of Level 3.

Note 2 - Summary of Significant Accounting Policies - Acquisition Earnout Liability Rollforward (Details) - Earn Out Liability [Member]	9 Months Ended
	Oct. 31, 2024 USD ($)
Beginning balance	$ 1,794,000
Settlement – common stock	(690,000)
Settlement – cash	(447,000)
Realized loss	159,000
Transfer out	(817,000)
Ending balance	$ 0

Note 11 - Subsequent Events (Details Textual)	Nov. 20, 2024 USD ($)
Revolving Credit Facility [Member] \| Subsequent Event [Member]
Proceeds from Lines of Credit	$ 1,000,000

Note 2 - Summary of Significant Accounting Policies - Schedule of Restructuring Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Restructuring reserve	$ 74	$ 0
Restructuring charges	0	749
Restructuring payments	(74)	0
Restructuring reserve	0	749
Restructuring costs incurred	759
Expected restructuring costs	759
Employee Severance Allocated to Cost of Sales [Member]
Restructuring reserve	0	0
Restructuring charges	0	154
Restructuring payments	0	0
Restructuring reserve	0	154
Restructuring costs incurred	154
Expected restructuring costs	154
Employee Severance Allocated to Selling, General, and Administrative [Member]
Restructuring reserve	74	0
Restructuring charges	0	350
Restructuring payments	(74)	0
Restructuring reserve	0	350
Restructuring costs incurred	350
Expected restructuring costs	350
Employee Severance Allocated to Research and Development [Member]
Restructuring reserve	0	0
Restructuring charges	0	227
Restructuring payments	0	0
Restructuring reserve	0	227
Restructuring costs incurred	227
Expected restructuring costs	227
Employee Severance [Member]
Restructuring reserve	74	0
Restructuring charges	0	731
Restructuring payments	(74)	0
Restructuring reserve	0	731
Restructuring costs incurred	731
Expected restructuring costs	731
Professional Fees and Licenses [Member]
Restructuring reserve	0	0
Restructuring charges	0	18
Restructuring payments	0	0
Restructuring reserve	0	$ 18
Restructuring costs incurred	28
Expected restructuring costs	$ 28

Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Oct. 31, 2024

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

Quoted

Significant

Prices in

Other

Significant

Active

Observable

Unobservable

Total Fair

Markets

Inputs

Value

(Level 1)

(Level 2)

(Level 3)

At January 31, 2024

Acquisition earnout liability (1)

1,794,000

—

1,794,000

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Nine-months ended
	October 31, 2024
Beginning balance	$	1,794,000
Settlement – common stock		(690,000	)
Settlement – cash		(447,000	)
Realized loss		159,000
Transfer out		(817,000	)
Ending balance	$	—

Disaggregation of Revenue [Table Text Block]

	Three Months Ended				Nine Months Ended
	October 31, 2024		October 31, 2023		October 31, 2024		October 31, 2023
Over time revenue	$	4,419,000	$	6,133,000	$	13,091,000	$	17,161,000
Point in time revenue		—		—		135,000		74,000
Total revenue	$	4,419,000	$	6,133,000	$	13,226,000	$	17,235,000

Accounting Standards Update and Change in Accounting Principle [Table Text Block]

		*January 31, 2024*				*CECL Adoption*				*Provision adjustments*				*Write-offs & Recoveries*				*October 31, 2024*
Allowance for credit losses		$	86,000			$	—				(58,000	)			31,000			$	59,000

		January 31, 2023				CECL Adoption				Provision adjustments				Write-offs & Recoveries				October 31, 2023
Allowance for credit losses		$	132,000			$	(36,000	)		$	—			$	—			$	96,000

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	*Three Months Ended*						*Nine Months Ended*
	*October 31, 2024*			*October 31, 2023*			*October 31, 2024*			*October 31, 2023*
Basic and diluted loss per share:
Net loss	$	(2,476,000	)	$	(11,911,000	)	$	(8,018,000	)	$	(17,327,000	)
Basic and diluted net loss per share of common stock	$	(0.61	)	$	(3.15	)	$	(2.01	)	$	(4.61	)
Weighted average shares outstanding – basic and diluted (1)(2)		4,055,268			3,780,689			3,981,406			3,756,420

Restructuring and Related Costs [Table Text Block]

	(in thousands)
										*As of October 31, 2024*
	*Accrued Balance as of*		*2024*		*2024*			*Accrued Balance as of*		*Total Costs*		*Total*
	*January 31, 2024*		*Expenses to Date*		*Cash Payments*			*October 31, 2024*		*Incurred to Date*		*Expected Costs*
Severance expense
Cost of sales	$	—	$	—	$	—		$	—	$	154	$	154
Selling, general, and administrative		74		—		(74	)		—		350		350
Research and development		—		—		—			—		227		227
Total severance expense	$	74	$	—	$	(74	)	$	—	$	731	$	731
Professional fees		—		—		—			—		28		28
Total	$	74	$	—	$	(74	)	$	—	$	759	$	759

	(in thousands)

	Accrued Balance as of		2023		2023		Accrued Balance as of
	January 31, 2023		Expenses to Date		Cash Payments		October 31, 2023
Severance expense
Cost of sales	$	—	$	154	$	—	$	154
Selling, general, and administrative		—		350		—		350
Research and development		—		227		—		227
Total severance expense	$	—	$	731	$	—	$	731
Professional fees		—		18		—		18
Total	$	—	$	749	$	—	$	749

Note 9 - Related Party Transactions (Details Textual) - USD ($)			3 Months Ended			9 Months Ended
	Feb. 07, 2024	Feb. 06, 2024	Oct. 31, 2024	Apr. 30, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Stock Issued During Period, Value, New Issues				$ 770,000
Matthew Etheridge [Member]
Related Party Transaction, Amounts of Transaction	$ 1,000,000
Matthew Etheridge [Member] \| Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		17,543
Shares Issued, Price Per Share (in dollars per share)		$ 5.7
Stock Issued During Period, Value, New Issues		$ 100,000
Rent Expense [Member] \| Former Employee of Avelead [Member]
Related Party Transaction, Amounts of Transaction			$ 0		$ 0	$ 0	$ 6,000

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details

Note 5 - Debt - Schedule of Debt to APR Ratio (Details)	3 Months Ended
Note 5 - Debt - Schedule of Debt to APR Ratio (Details)	Jan. 31, 2025	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024
Debt to APR ratio		0.4	0.45	0.5
Forecast [Member]
Debt to APR ratio	0.35

Note 4 - Operating Leases

9 Months Ended

Oct. 31, 2024

Lessee, Operating Leases [Text Block]

NOTE 4 — OPERATING LEASES

We determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate for the expected remaining lease term at commencement date for new and existing leases in determining the present value of future lease payments. Operating lease expense is recognized on a straight-line basis over the lease term.

The Company has moved to a virtual office model and does not have a physical office space. Membership agreements and daily space rentals are leveraged by the Company when groups need to meet in person with the costs expensed as incurred. For the three and nine months ended October 31, 2024 and 2023, the Company recorded $9,000 and $25,000, respectively, and $6,000 and $16,000, respectively, related to such office space rentals.

Alpharetta Office Lease

On October 1, 2021, the Company entered into an agreement with a third-party to sublease its office space in Alpharetta, Georgia. The sublease term was for 18 months, which coincided with the Company’s underlying lease (see below). The Company received $292,000 from the sublessee over the term of the sublease. The sublease did not relieve the Company of its original obligation under the lease, and therefore the Company did not adjust the operating lease right-of-use asset and related liability. The sublease terminated on March 31, 2023. For the nine months ended October 31, 2024 and 2023, the Company recorded $0 and $32,000, respectively, as other income related to the sublease. There was no income related to the sublease in the three months ended October 31, 2024 and 2023.

The Company entered into a lease for office space in Alpharetta, Georgia, on March 1, 2020. The lease terminated on March 31, 2023. At inception, the Company recorded a right-of use asset of $540,000, and related current and long-term operating lease obligation in the accompanying consolidated balance sheet. The Company used a discount rate of 6.5% to determine the lease liability. For the nine months ended October 31, 2024 and 2023, the Company had lease operating costs of approximately $0 and $32,000, respectively. There was no expense related to lease operating costs in the three months ended October 31, 2024 and 2023.

Suwanee Office Lease

Upon acquiring Avelead on August 16, 2021 (refer to Note 3 – Business Combination), the Company assumed an operating lease agreement for the corporate office space of Avelead. The lessor is an entity controlled by one of the Sellers and that Seller is a former employee of the Company. The initial 36-month term lease commenced March 1, 2019, and expired on February 28, 2022. The Company previously renewed the lease for an additional 12-month term which expired February 28, 2023, and was not renewed. For the nine months ended October 31, 2024 and 2023, the Company recorded rent expense of $0 and $6,000, respectively. There was no expense recorded for the three months ended October 31, 2024 and 2023.

Note 4 - Operating Leases (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		18 Months Ended
Note 4 - Operating Leases (Details Textual) - USD ($)	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Mar. 31, 2023	Oct. 01, 2021	Aug. 16, 2021	Mar. 01, 2020
Membership Agreements and Daily Space Rentals [Member]
Operating Lease, Expense	$ 9,000	$ 6,000	$ 25,000	$ 16,000
Alpharetta Sublease [Member]
Lessor, Operating Lease, Term of Contract (Month)						18 months
Sublease Income	0	0	0	32,000	$ 292,000
Alpharetta Office Lease [Member]
Operating Lease, Right-of-Use Asset								$ 540,000
Lessee, Operating Lease, Discount Rate								6.50%
Operating Lease, Cost	0	0	0	32,000
Suwanee Office Lease [Member]
Operating Lease, Expense	$ 0	$ 0	$ 0	$ 6,000
Lessee, Operating Lease, Term of Contract (Month)							36 months
Lessee, Operating Lease, Renewal Term (Month)							12 months

Note 6 - Income Taxes

9 Months Ended

Oct. 31, 2024

Income Tax Disclosure [Text Block]

NOTE 6 — INCOME TAXES

Income tax expense was $0 for the nine months ended October 31, 2024, compared to income tax benefit of $59,000 in the prior year comparable period. The effective income tax rate on continuing operations of approximately 0% differs from our combined federal and state statutory rate of 24% primarily due to the full valuation allowance the Company currently maintains on its net deferred tax asset.

The Company has recorded $346,000 and $340,000 in reserves for uncertain tax positions as of October 31, 2024 and January 31, 2024, respectively.

The Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2020. All material state and local income tax matters have been concluded for years through January 31, 2019. The Company is no longer subject to IRS examination for periods prior to the tax year ended January 31, 2020; however, carryforward losses that were generated prior to the tax year ended January 31, 2020, may still be adjusted by the IRS if they are used in a future period.

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Note 5 - Debt (Details Textual)		3 Months Ended	9 Months Ended
Note 5 - Debt (Details Textual)	Nov. 29, 2022 USD ($)	Apr. 30, 2024 USD ($)	Oct. 31, 2024 USD ($) $ / shares	May 24, 2024 shares	Feb. 01, 2024 USD ($) shares	Jan. 31, 2024 USD ($)
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Prime Rate [Member]
Common Stock Warrant [Member]
Derivative Liability					$ 881,000
Professional Fees		$ 46,000
Maximum [Member]
Common Stock, Shares, Outstanding, Percent			9.99%
Non Directors and Officers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares			$ 5.7
Directors and Officers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares			$ 5.85
Securities Purchase Agreement February 2024 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares					267,728
Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares				267,728
Term Loan [Member]
Debt Instrument, Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Rate Floor	3.25%
Debt Instrument, Face Amount	$ 10,000,000
Debt Instrument, Term (Year)	5 years
Long-Term Debt, Maturity, Year Two			$ 500,000
Long-Term Debt, Maturity, Year Three			1,000,000
Long-Term Debt, Maturity, Year Four			2,000,000
Long-Term Debt, Maturity, Year Five			$ 3,000,000
Term Loan and Revolving Line of Credit [Member]
Debt Instrument, Basis Spread on Variable Rate			1.50%
Debt Instrument, Basis Rate Floor			3.25%
Debt Instrument, Covenant, Fixed Charge Coverage Ratio			1.2
Amortization of Debt Issuance Costs			$ 250,000
Debt Instrument, Unamortized Discount			179,000			$ 193,000
Unsecured Subordinated Promissory Notes [Member]
Debt Instrument, Face Amount			4,400,000
Debt Instrument, Interest Rate, Effective Percentage					15.00%
Debt Instrument, Fair Value Disclosure			3,538,000
Debt Instrument, Unamortized Discount			862,000
Debt Issuance Costs, Gross			$ 183,000
Unsecured Subordinated Promissory Notes [Member] \| Securities Purchase Agreement February 2024 [Member]
Debt Instrument, Face Amount					$ 4,400,000
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,000,000
Debt Instrument, Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Rate Floor	3.25%

Note 5 - Debt - Schedule of Minimum Adjusted EBITDA (Details) - USD ($)	Jan. 31, 2025	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024
Minimum Adjusted EBITDA		$ (1,500,000)	$ (2,960,000)	$ (4,560,000)	$ (5,750,000)
Forecast [Member]
Minimum Adjusted EBITDA	$ 430,000

Note 5 - Debt

9 Months Ended

Oct. 31, 2024

Debt Disclosure [Text Block]

NOTE 5 — DEBT

Outstanding principal balances consisted of the following at October 31, 2024:

	*October 31, 2024*			*January 31, 2024*
Term loan	$	8,000,000		$	9,000,000
Financing cost payable		177,000			135,000
Less: Deferred financing cost		(44,000	)		(69,000	)
Total		8,133,000			9,066,000
Less: Current portion of term loan		(2,250,000	)		(1,500,000	)
Non-current portion of term loan	$	5,883,000		$	7,566,000

	October 31, 2024			January 31, 2024
Notes payable and accrued interest	$	4,907,000		$	—
Less: Discount on notes payable		(642,000	)		—
Less: Deferred financing costs		(136,000	)		—
Total		4,129,000			—
Less: Current portion of notes payable		—			—
Non-current portion of notes payable	$	4,129,000		$	—

Term Loan and Revolving Line of Credit

On November 29, 2022, the Company executed a Second Modification to Second Amended and Restated Loan Agreement (the “Second Modification”). The Second Modification includes an expansion of the Company’s total borrowing to include a $2,000,000 non-formula revolving line of credit. The revolving line of credit will be co-terminus with the term loan and matures on August 26, 2026. Amounts outstanding under the line of credit portion of the Second Amended and Restated Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5%, with a Prime “floor” rate of 3.25%. The Second Modification amended certain financial covenants in the Second Amended and Restated Loan Agreement.

Under the Second Amended and Restated Loan Agreement, the Company has a term loan facility with an initial maximum principal amount of $10,000,000. Amounts outstanding under the Second Amended and Restated Loan Agreement bear interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5%, with a Prime “floor” rate of 3.25%. The Second Amended and Restated Loan Agreement has a five-year term, and the maximum principal amount was advanced in a single-cash advance on or about the original closing date ( August 2021). Interest is due monthly, and the Company shall make monthly interest-only payments through the one-year anniversary of the original closing date. Under the Second Amended and Restated Loan Agreement, principal repayments are required of $500,000 in the second year, $1,000,000 in the third year, $2,000,000 in the fourth year, and $3,000,000 in the fifth year with the remaining outstanding principal balance and all accrued but unpaid interest due in full on the maturity date. The Second Amended and Restated Loan Agreement may also require early repayments if certain conditions are met.

The Company executed a Third Modification and Waiver to Second Amended and Restated Loan Agreement (the “Third Modification”) and a Fourth Modification to Second Amended and Restated Loan Agreement (the “Fourth Modification”) on February 7, 2024 and April 5, 2024, respectively (collectively, the “Third and Fourth Modifications”). The Third and Fourth Modifications reestablished the customary financial covenants for the Second Amended and Restated Loan Agreement as follows:

●

Minimum Adjusted EBITDA. Commencing with the quarter ending January 31, 2024, the Company shall maintain Adjusted EBITDA, measured on a quarterly basis as of the last day of each fiscal quarter, in an amount not less than the amounts (or, in the case of amounts set forth in parentheses, no worse than the amounts) set forth under the heading “Minimum Adjusted EBITDA” as of, and for each of the dates appearing adjacent to such “Minimum Adjusted EBITDA.”

	Minimum
Quarter Ending	Adjusted EBITDA
January 31, 2024	$	(5,750,000	)
April 30, 2024		(4,560,000	)
July 31, 2024		(2,960,000	)
October 31, 2024		(1,500,000	)
January 31, 2025		430,000

●

Maximum ARR Net Leverage Ratio. The Company's ARR Net Leverage Ratio, measured on a quarterly basis as of the last day of each fiscal quarter, shall not be greater than the amount set forth under the heading “Maximum ARR Net Leverage Ratio” as of, and for each of the dates appearing adjacent to such “Maximum ARR Net Leverage Ratio.”

	*Maximum*
	*ARR Net Leverage*
Quarter Ending	*Ratio*
April 30, 2024		0.50 to 1.00
July 31, 2024		0.45 to 1.00
October 31, 2024		0.40 to 1.00
January 31, 2025		0.35 to 1.00

●

Maximum Debt to Adjusted EBITDA Ratio. Commencing with the quarter ending April 30, 2025, the Company's Maximum Debt to Adjusted EBITDA Ratio, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended, shall not be greater than the amount set forth under the heading “Maximum Debt to Adjusted EBITDA Ratio” as of, and for each of the dates appearing adjacent to such “Maximum Debt to Adjusted EBITDA Ratio.”

	*Maximum*
	*Debt to Adjusted*
	*EBITDA*
Quarter Ending	*Ratio*
April 30, 2025		3.50 to 1.00
July 31, 2025		3.00 to 1.00
October 31, 2025		2.50 to 1.00
January 31, 2026 and on the last day of each quarter thereafter		2.00 to 1.00

●

Fixed Charge Coverage Ratio. Commencing with the quarter ending April 30, 2025, the Company shall maintain a Fixed Charge Coverage Ratio of not less than 1.20 to 1.00, measured on a quarterly basis as of the last day of each fiscal quarter for the trailing four (4) quarter period then ended.

On November 13, 2024, the Company executed the Fifth Modification to Second Amended and Restated Loan and Security Agreement (the “Fifth Modification”) that amended, among other things, the Minimum Adjusted EBITDA and Maximum ARR Net Leverage Ratio covenants. Refer to Note 11 – Subsequent Events for additional information regarding the Fifth Modification.

The Second Amended and Restated Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness, certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including a cross default provision with the Second Amended and Restated Loan Agreement and a change of control default provision. The line of credit also is subject to customary prepayment requirements. Substantially all the assets of the Company are collateralized by the Second Amended and Restated Loan Agreement. For the period ended October 31, 2024, the Company was not in compliance with certain covenants under the Second Amended and Restated Loan and Security Agreement. Subsequent to the period ended October 31, 2024, the Company entered into the Fifth Modification, whereby certain covenants were modified. As a result, the Company was in compliance with all modified debt covenants. However, the Company’s current forecast projects the Company may not be able to maintain compliance with certain of its financial covenants under the Second Amended and Restated Loan Agreement in the future. Refer to Note 1 – Basis of Presentation for detail regarding the Company’s assessment as a going concern.

The Company records costs related to the maintenance of the Second Amended and Restated Loan Agreement as deferred financing costs, net of the term loan. These deferred financing costs are being amortized over the remaining term of the loan. The Company has incurred $250,000 in financing costs which become payable at the earlier of the term date of the loan, or pre-payment. These costs are being accreted, through interest expense, to the full value of the $250,000 over the remaining term of the loan.

Debt Private Placement

On February 1, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors, including certain directors and officers of the Company (collectively, the “Investors”), pursuant to which the Company agreed to sell to the Investors unsecured subordinated promissory notes (the “Notes”) in the aggregate principal amount of $4.4 million and warrants (the “Warrants”) to purchase up to an aggregate of 267,728 shares of the Company’s common stock in a private placement (the “Debt Private Placement”). The closing of the Debt Private Placement occurred on February 7, 2024 (the “Closing Date”).

Notes Payable

The Notes bear interest at a rate of 15% per annum and mature on August 7, 2026 (the “Maturity Date”). All accrued and unpaid interest on the Notes will be capitalized and added to the outstanding principal balance of the Notes and will be payable in cash on the Maturity Date. The Company may redeem the Notes, in whole or in part, prior to the Maturity Date without any premium or penalty. In the event the Company prepays any portion of the then outstanding principal balance of the Notes on or before the twelve (12) month anniversary of the Closing Date, in addition to such prepayment of the principal balance, the Company must pay to the Investors a prepayment fee (in accordance with the each Investor’s pro-rata share of the Notes) in an amount equal to the amount of interest that would have accrued but for the prepayment from the date of such prepayment through such twelve (12) month anniversary of the Closing Date.

The Notes also include customary negative covenants, subject to exceptions, which limit dispositions of assets and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including a cross default provision with the Second Amended and Restated Loan Agreement and a change of control default provision.

The rights of each Investor to receive payments under the Notes are subordinate to the rights of Western Alliance Bank (“WAB”), pursuant to a subordination agreement which the Investors entered into with WAB concurrently with the Debt Private Placement.

The Company allocated the original total proceeds at inception from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 – Equity) across the securities issued in connection with the offerings. The Company has recorded the Notes at a relevant residual fair value of $3,538,000, consisting of the $4,400,000 face value of the notes and $862,000 discount. The Company allocated $183,000 in issuance costs. The discount is being accreted and the financing costs amortized as interest expense over the term of the Notes using the effective interest method.

Warrants

The Warrants have an exercise price of $5.70 (except for Warrants issued to the Company’s directors and officers which have an exercise price of $5.85), are immediately exercisable, and will expire on the fourth anniversary of the Closing Date. The Warrants are subject to customary adjustments for certain transactions affecting the Company’s capitalization. The terms of the Warrants preclude a holder thereof from exercising such holder’s Warrants, and the Company from giving effect to such exercise, if after giving effect to the issuance of common stock upon such exercise, the holder (together with the holder’s affiliates and any other persons acting as a group together with the holder or any of the holder’s affiliates) would beneficially own in excess of 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of common stock upon such exercise.

The Notes and the Warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the common stock underlying the Warrants, were "restricted securities" under the Securities Act or applicable state securities laws. Accordingly, the Notes, the Warrants and the common stock underlying the Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements and in accordance with applicable state securities laws. The securities were offered and sold to “accredited investors” as that term is defined in Rule 501(a) under the Securities Act.

The Warrants contain a registration rights provision for the Company to provide the Warrant holder with registered common stock upon their exercise of a Warrant. If the Company is not able to deliver registered common stock for exercised Warrants that results in the Warrant holder acquiring registered common stock, then the Warrant holder has the discretion to request the Company remit cash compensation up to the corresponding purchase price. Accordingly, the Company determined the feature required liability accounting treatment upon issuance. On May 7, 2024, the Company filed a Registration Statement on Form S-3 (Registration No. 333-279190), as amended by that certain Pre-Effective Amendment No. 1 to Form S-3 filed on May 24, 2024 (collectively, the “Registration Statement”), for purpose of registering for resale 267,728 shares of common stock underlying the Warrants. The Registration Statement was declared effective by the SEC on June 10, 2024. The filing of the Registration Statement eliminated the potential cash settlement feature that caused liability accounting ensuring the Warrants will be settled with shares, and accordingly, the Warrants met the criteria for equity classification and reclassified them to paid in capital after a final re-measurement.

The Company allocated the total proceeds from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 – Equity) across the securities issued in connection with offerings. The Company recorded an initial liability of $881,000 for the Warrants at fair value using a Black-Scholes model. The Company immediately recognized $46,000 in issuance costs as expense related to the agreements for the Warrants. For the three months ended July 31, 2024, the Company reclassified the $837,000 remeasured value of the Warrants as additional paid in capital on the condensed consolidated Balance Sheet.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Note 10 - Goodwill and Intangible Assets (Tables)

9 Months Ended

Oct. 31, 2024

Schedule of Goodwill [Table Text Block]

	Nine Months Ended
	October 31, 2023
Balance as of January 31, 2023	$	23,089,000
Impairment		(9,813,000	)
Balance as of October 31, 2023	$	13,276,000

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Note 11 - Subsequent Events - Schedule of Minimum Adjusted EBITDA (Details) - USD ($)	Apr. 30, 2025	Jan. 31, 2025	Dec. 31, 2024	Nov. 30, 2024	Oct. 31, 2024	Sep. 30, 2024	Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024
Minimum Adjusted EBITDA					$ (1,500,000)		$ (2,960,000)	$ (4,560,000)	$ (5,750,000)
Forecast [Member]
Minimum Adjusted EBITDA		$ 430,000
Fifth Modification, Term Loan [Member]
Minimum Adjusted EBITDA					$ (500,000)	$ (225,000)
Fifth Modification, Term Loan [Member] \| Forecast [Member]
Minimum Adjusted EBITDA	$ 0		$ (100,000)
Fifth Modification, Term Loan [Member] \| Subsequent Event [Member]
Minimum Adjusted EBITDA				$ (150,000)

Unaudited Condensed Consolidated Statements of Operations - USD ($)

3 Months Ended

9 Months Ended

Oct. 31, 2024

Oct. 31, 2023

Oct. 31, 2024

Oct. 31, 2023

Revenues:

$ 4,419,000

$ 6,133,000

$ 13,226,000

$ 17,235,000

Selling, general and administrative expense

2,880,000

4,122,000

9,060,000

12,079,000

Research and development

1,134,000

1,304,000

3,569,000

4,310,000

Impairment of goodwill

9,813,000

Impairment of long-lived assets

963,000

Total operating expenses

6,399,000

19,080,000

19,670,000

35,776,000

Operating loss

(1,980,000)

(12,947,000)

(6,444,000)

(18,541,000)

Other (expense) income:

Interest expense

(496,000)

(266,000)

(1,457,000)

(781,000)

Valuation adjustments

1,182,000

(115,000)

1,905,000

Other

(2,000)

31,000

Loss before income taxes

(2,476,000)

(12,031,000)

(8,018,000)

(17,386,000)

Income tax benefit

120,000

59,000

Net loss

$ (2,476,000)

$ (11,911,000)

$ (8,018,000)

$ (17,327,000)

Basic and Diluted Earnings Per Share:

Net loss per common share – basic and diluted (in dollars per share)

$ (0.61)

$ (3.15)

$ (2.01)

$ (4.61)

Weighted average number of common shares – basic and diluted (in shares)

^[1],[2]

4,055,268

3,780,689

3,981,406

3,756,420

Software as a Service [Member]

Revenues:

$ 2,933,000

$ 3,924,000

$ 8,734,000

$ 10,630,000

Cost of goods and services

1,512,000

1,677,000

4,356,000

5,159,000

Maintenance [Member]

Revenues:

878,000

1,070,000

2,651,000

3,327,000

Cost of goods and services

42,000

129,000

127,000

250,000

Professional Fees and Licenses [Member]

Revenues:

608,000

1,139,000

1,841,000

3,278,000

Cost of goods and services

$ 831,000

$ 1,072,000

$ 2,558,000

$ 3,202,000

[1]

Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three and nine months ended October 31, 2024, diluted earnings per share excludes 4,396 outstanding stock options, 220,327 unvested restricted shares of common stock, and 237,027 shares of common stock issuable through the exercise of warrants. For the three and nine months ended October 31, 2023, diluted earnings per share excludes 27,919 outstanding stock options and 132,013 unvested restricted shares of common stock.

[2]

Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of October 31, 2024 and 2023, there were 220,327 and 132,013 unvested restricted shares of common stock outstanding, respectively.

Note 3 - Business Combination

9 Months Ended

Oct. 31, 2024

Business Combination Disclosure [Text Block]

NOTE 3 — BUSINESS COMBINATION

Avelead Acquisition

The Company acquired all the equity interests of Avelead Consulting, LLC (“Avelead”) as part of the Company’s strategic expansion into the acute-care health care revenue cycle management industry (the “Transaction”). The Transaction was completed on August 16, 2021.

As of January 31, 2024, the estimated aggregate value of the second year earnout consideration was $1,794,000. On March 27, 2024, the Company issued 105,958 unregistered securities in the form of restricted common stock, par value $0.01 per share, with respect to the second year earnout consideration. For the three and nine months ended October 31, 2024, the Company made cash payments of $200,000 and $887,000 respectively, related to the second year earnout consideration. The remaining outstanding amounts were originally contractually due by October 31, 2024. The remaining cash liability is reflected on the Company’s condensed consolidated balance sheet as “acquisition earnout liability” and totaled $377,000 as of October 31, 2024.

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Oct. 31, 2024	Dec. 16, 2024
Document Information [Line Items]
Entity Central Index Key	0001008586
Entity Registrant Name	STREAMLINE HEALTH SOLUTIONS INC.
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 31, 2024
Document Transition Report	false
Entity File Number	000-28132
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1455414
Entity Address, Address Line One	2400 Old Milton Pkwy., Box 1353
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30009
City Area Code	888
Local Phone Number	997-8732
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	STRM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,273,175

Note 11 - Subsequent Events

9 Months Ended

Oct. 31, 2024

Subsequent Events [Text Block]

NOTE 11- SUBSEQUENT EVENTS

Loan Modification

On November 13, 2024, the Company executed the Fifth Modification to Second Amended and Restated Loan and Security Agreement. The Fifth Modification updated the definition of “Adjusted EBITDA” and amended certain financial covenants as follows:

Maximum ARR Net Leverage Ratio. Commencing with the month ended September 30, 2024, Borrowers’ ARR Net Leverage Ratio, measured on a monthly basis as of the last day of each month, shall not be greater than the amount set forth under the heading “Maximum ARR Net Leverage Ratio” as of, and for each of the dates appearing adjacent to such “Maximum ARR Net Leverage Ratio.”

	Maximum
	ARR Net Leverage
Month Ending	Ratio
September 30, 2024		0.68 to 1.00
October 31, 2024		0.66 to 1.00
November 30, 2024		0.64 to 1.00
December 31, 2024		0.60 to 1.00
January 31, 2025		0.35 to 1.00
April 30, 2025		0.35 to 1.00

Minimum Adjusted EBITDA. Commencing with the month ended September 30, 2024, Borrowers shall maintain Adjusted EBITDA, measured on a monthly basis as of the last day of each month, in an amount not less than the amounts (or, in the case of amounts set forth in parentheses, no worse than the amounts) set forth under the heading “Minimum Adjusted EBITDA” as of, and for each of the dates appearing adjacent to such “Minimum Adjusted EBITDA.”

	Minimum
Month Ending	Adjusted EBITDA
September 30, 2024	$	(225,000	)
October 31, 2024		(500,000	)
November 30, 2024		(150,000	)
December 31, 2024		(100,000	)
January 31, 2025 and on the last day of each month thereafter through April 30, 2025		0

The Fifth Modification also requires the Company to pay certain fees to Western Alliance Bank in connection with the extension of credit and subsequent repayment of obligations due to Western Alliance Bank under the Second Amended and Restated Loan and Security Agreement. The foregoing fees, if any, will be due and payable on the earlier of (i) August 26, 2026, and (ii) the date on which the Company repays in full all obligations due to Western Alliance Bank under the Second Amended and Restated Loan and Security Agreement.

Line of Credit Draw

On November 20, 2024, the Company received a $1,000,000 draw from its revolving line of credit under the Second Amended and Restated Loan Agreement as detailed in Note 5 – Debt.

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Net loss	$ (8,018,000)	$ (17,327,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,594,000	3,264,000
Accrued interest expense - notes payable	507,000	0
Valuation adjustments	115,000	(1,905,000)
Benefit for deferred income taxes	0	(104,000)
Share-based compensation expense	1,483,000	1,626,000
Impairment of goodwill	0	9,813,000
Impairment of long-lived assets	0	963,000
Provision for credit losses	(58,000)	0
Changes in assets and liabilities:
Accounts and contract receivables	1,003,000	4,299,000
Other assets	(116,000)	(65,000)
Accounts payable	357,000	109,000
Accrued expenses and other liabilities	(505,000)	(417,000)
Deferred revenue	(1,000,000)	(2,417,000)
Net cash used in operating activities	(2,638,000)	(2,161,000)
Cash flows from investing activities:
Purchases of property and equipment	0	(47,000)
Capitalization of software development costs	(667,000)	(1,562,000)
Net cash used in investing activities	(667,000)	(1,609,000)
Cash flows from financing activities:
Repayment of bank term loan	(1,000,000)	(500,000)
Repayment of line of credit	(1,500,000)	0
Proceeds from issuance of common stock	100,000	0
Proceeds from notes payable	4,400,000	0
Proceeds from line of credit	0	500,000
Payments of acquisition earnout liabilities	(886,000)	0
Payments for deferred financing costs	(168,000)	0
Repurchase of common shares to satisfy employee tax withholding	(77,000)	(271,000)
Net cash provided (used in) by financing activities	869,000	(271,000)
Net decrease in cash and cash equivalents	(2,436,000)	(4,041,000)
Cash and cash equivalents at beginning of period	3,190,000	6,598,000
Cash and cash equivalents at end of period	$ 754,000	$ 2,557,000

Note 9 - Related Party Transactions (Tables)

9 Months Ended

Oct. 31, 2024

Name of Investor	Investment Amount		Warrants Granted
121G, LLC (1)	$	1,000,000		59,829
Matthew W. Etheridge (2)		1,000,000		61,403
Jonathan R. Phillips (3)		50,000		2,991
The Ferayorni Family Trust (4)		500,000		29,914

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Total revenues	$ 4,419,000	$ 6,133,000	$ 13,226,000	$ 17,235,000
Transferred over Time [Member]
Total revenues	4,419,000	6,133,000	13,091,000	17,161,000
Transferred at Point in Time [Member]
Total revenues	$ 0	$ 0	$ 135,000	$ 74,000

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

Note 1 - Basis of Presentation

9 Months Ended

Oct. 31, 2024

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]

NOTE 1 — BASIS OF PRESENTATION

Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries, Streamline Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay & Benefits, LLC, (collectively, unless the context requires otherwise, “we,” “us,” “our,” “Streamline,” or the “Company”), operate in one segment as a provider of healthcare information technology solutions and associated services. The Company provides these capabilities through the licensing of its Coding & Clinical Documentation Improvement (CDI) solutions, eValuator coding analysis platform, RevID, and other workflow software applications and the use of such applications by software as a service (“SaaS”). The Company also provides audit services to help clients optimize their internal clinical documentation and coding functions, as well as implementation and consulting services to complement its software solutions. The Company’s software and services enable hospitals and integrated healthcare delivery systems in the United States and Canada to capture, store, manage, route, retrieve and process patient clinical, financial and other healthcare provider information related to the patient revenue cycle.

The accompanying unaudited condensed consolidated financial statements have been prepared by us pursuant to the rules and regulations applicable to quarterly reports on Form 10-Q of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. The condensed consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s most recent annual report on Form 10-K. Operating results for the three and nine months ended October 31, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2025.

The Company has one operating segment and one reporting unit due to the singular nature of our products, product development and distribution process, and client base as a provider of computer software-based solutions and services for acute-care healthcare providers.

All amounts in the condensed consolidated financial statements, notes and tables have been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated. All references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following calendar year.

Going Concern

The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. To date, the Company has not generated sufficient revenues to allow it to generate cash flow from operations and the Company anticipates the need for additional liquidity in the next twelve months. The Company has historically accumulated losses and used cash from its financing activities to supplement its operations. The Company’s current forecast projects the Company may not be able to maintain compliance with certain of its financial covenants under its current credit agreement with the term loan lender in the next twelve months. Further, our recent private placement notes payables have cross-default conditions with the senior term loan debt. These conditions raise substantial doubt about the ability of the Company to continue as a going concern within one year after the date that the financial statements are issued.

In view of these matters, continuation as a going concern is dependent upon the Company’s ability to achieve cash from operations and raise additional debt or equity capital to fund its ongoing operations.

As of October 31, 2024, the Company had approximately $12.3 million of total outstanding debt associated with its term loan and private placement notes payables, $2.3 million of which is classified as a current liability. The Company’s ability to refinance its existing debt is based upon credit markets and economic forces that are outside of its control. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company.

The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern.

Reverse Stock Split

On September 25, 2024, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation to effect a 1-for-15 reverse stock split pursuant to which each 15 shares of the Company’s issued and outstanding common stock immediately prior to the effective time, which was 12:01 am Eastern Daylight Time on October 4, 2024, were combined into one share of the Company’s common stock, without effecting a change to the par value per share of Common Stock. The Company’s common stock began trading on a split-adjusted basis when the market opened on October 4, 2024.

The Reverse Stock Split did not change the Company's authorized number of shares of common stock. The Reverse Stock Split did not change the par value of the common stock, therefore, the Company recorded an increase to additional paid in capital of $551,000 as of January 31, 2024 and an offsetting adjustment to the carrying value of common stock. No fractional shares were issued in connection with the Reverse Stock Split, and stockholders who would otherwise have been entitled to receive a fractional share instead received a cash payment equal to the fraction of a share of common stock in lieu of such fractional share. Proportionate adjustments were made to the number of shares authorized under the Company’s equity incentive plans, the number of shares subject to any award or purchase right under the Company’s equity incentive plans, and the exercise price or purchase price with respect to any stock option award or purchase right under the Company’s equity incentive plans. All shares of the Company’s common stock, stock-based instruments and per-share data included in these condensed consolidated financial statements have been retrospectively adjusted as though the Reverse Stock Split has been effected prior to all periods presented. All of the Company's equity incentive plans included existing conversion language in the event of a stock split and thus did not result in modification accounting or additional incremental expense as a result of this transaction.

Note 5 - Debt (Tables)

9 Months Ended

Oct. 31, 2024

Schedule of Debt [Table Text Block]

	*October 31, 2024*			*January 31, 2024*
Term loan	$	8,000,000		$	9,000,000
Financing cost payable		177,000			135,000
Less: Deferred financing cost		(44,000	)		(69,000	)
Total		8,133,000			9,066,000
Less: Current portion of term loan		(2,250,000	)		(1,500,000	)
Non-current portion of term loan	$	5,883,000		$	7,566,000

	October 31, 2024			January 31, 2024
Notes payable and accrued interest	$	4,907,000		$	—
Less: Discount on notes payable		(642,000	)		—
Less: Deferred financing costs		(136,000	)		—
Total		4,129,000			—
Less: Current portion of notes payable		—			—
Non-current portion of notes payable	$	4,129,000		$	—

Schedule Of Minimum Adjusted EBITDA [Table Text Block]

	Minimum
Quarter Ending	Adjusted EBITDA
January 31, 2024	$	(5,750,000	)
April 30, 2024		(4,560,000	)
July 31, 2024		(2,960,000	)
October 31, 2024		(1,500,000	)
January 31, 2025		430,000

Schedule of Debt to APR Ratios [Table Text Block]

	*Maximum*
	*ARR Net Leverage*
Quarter Ending	*Ratio*
April 30, 2024		0.50 to 1.00
July 31, 2024		0.45 to 1.00
October 31, 2024		0.40 to 1.00
January 31, 2025		0.35 to 1.00

Schedule of Debt, Adjusted EBITDA [Table Text Block]

	*Maximum*
	*Debt to Adjusted*
	*EBITDA*
Quarter Ending	*Ratio*
April 30, 2025		3.50 to 1.00
July 31, 2025		3.00 to 1.00
October 31, 2025		2.50 to 1.00
January 31, 2026 and on the last day of each quarter thereafter		2.00 to 1.00

Note 9 - Related Party Transactions

9 Months Ended

Oct. 31, 2024

NOTE 9 - RELATED PARTY TRANSACTIONS

Avelead Office Lease

The Company acquired Avelead on August 16, 2021. Accordingly, the Company assumed a lease for corporate office space from one of the selling shareholders of Avelead who was employed by the company through August 2023. This lease term ended February 2023. For the nine months ended October 31, 2024 and 2023, the Company recorded rent expense of $0 and $6,000, respectively. There was no expense recorded in the three months ended October 31, 2024 and 2023. Refer to Note 3 – Business Combination for additional information.

Debt Private Placement

The following related parties participated in the Debt Private Placement (Refer to Note 5 – Debt for additional information):

Name of Investor	Investment Amount		Warrants Granted
121G, LLC (1)	$	1,000,000		59,829
Matthew W. Etheridge (2)		1,000,000		61,403
Jonathan R. Phillips (3)		50,000		2,991
The Ferayorni Family Trust (4)		500,000		29,914

(1) The securities held in the account of 121G, LLC (“121G”) may be deemed to be beneficially owned by Wyche “Tee” Green, III, the managing member of 121G. Mr. Green serves as Executive Chairman of the Company and is a member of the Board.

(2) Mr. Etheridge became a member of the Board subsequent to the closing of the Debt Private Placement.
(3) Mr. Phillips is a member of the Board.
(4) The securities held in the account of The Ferayorni Family Trust may be deemed to be beneficially owned by Justin J. Ferayorni as co-trustee of The Ferayorni Family Trust. Mr. Ferayorni is a member of the Board.

Common Stock Private Placement

On February 6, 2024, the Company completed the sale of 17,543 shares of the Company’s common stock to Matthew Etheridge at a purchase price of $5.70 per share for an aggregate purchase price of $100,000. Mr. Etheridge became a director of the Company subsequent to the closing of the Debt Private Placement.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Note 2 - Summary of Significant Accounting Policies - Accounting Standards Update (Details) - USD ($)	9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Allowance for credit losses	$ 86,000	$ 132,000
Allowance for credit losses, provision	(58,000)	0
Allowance for credit losses, writeoffs	31,000	0
Allowance for credit losses	59,000	96,000
Cumulative Effect, Period of Adoption, Adjustment [Member] \| Accounting Standards Update 2016-13 [Member]
Allowance for credit losses	$ 0	$ (36,000)

Note 11 - Subsequent Events - Schedule of Debt to APR Ratio (Details)	1 Months Ended						3 Months Ended
	Apr. 30, 2025	Jan. 31, 2025	Dec. 31, 2024	Nov. 30, 2024	Oct. 31, 2024	Sep. 30, 2024	Jan. 31, 2025	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024
Debt to APR ratio								0.4	0.45	0.5
Forecast [Member]
Debt to APR ratio							0.35
Fifth Modification, Term Loan [Member] \| Minimum [Member]
Debt to APR ratio			0.6	0.64	0.66	0.68
Fifth Modification, Term Loan [Member] \| Minimum [Member] \| Forecast [Member]
Debt to APR ratio	0.35	0.35
Fifth Modification, Term Loan [Member] \| Maximum [Member]
Debt to APR ratio			1	1	1	1
Fifth Modification, Term Loan [Member] \| Maximum [Member] \| Forecast [Member]
Debt to APR ratio	1	1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Oct. 31, 2024	Jan. 31, 2024
Allowance for credit losses	$ 59,000	$ 86,000
Accumulated amortization	328,000	291,000
Capitalized software accumulated amortization	9,368,000	7,960,000
Intangible assets, accumulated amortization	$ 5,246,000	$ 4,019,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	85,000,000	85,000,000
Common stock, shares issued (in shares)	4,265,821	3,929,446
Common stock, shares outstanding (in shares)	4,265,821	3,929,446

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Oct. 31, 2024	Jan. 31, 2024
Current assets:
Cash and cash equivalents	$ 754,000	$ 3,190,000
Accounts receivable, net of allowance for credit losses of $59,000 and $86,000, respectively	2,824,000	4,237,000
Contract receivables	1,248,000	780,000
Prepaid and other current assets	567,000	629,000
Total current assets	5,393,000	8,836,000
Non-current assets:
Property and equipment, net of accumulated amortization of $328,000 and $291,000 respectively	52,000	88,000
Capitalized software development costs, net of accumulated amortization of $9,368,000 and $7,960,000, respectively	5,165,000	5,798,000
Intangible assets, net of accumulated amortization of $5,246,000 and $4,019,000, respectively	10,844,000	12,071,000
Goodwill	13,276,000	13,276,000
Other	1,236,000	1,666,000
Total non-current assets	30,573,000	32,899,000
Total assets	35,966,000	41,735,000
Current liabilities:
Accounts payable	1,610,000	1,253,000
Accrued expenses	1,518,000	2,023,000
Current portion of term loan	2,250,000	1,500,000
Deferred revenues	6,095,000	7,112,000
Acquisition earnout liability	377,000	1,794,000
Total current liabilities	11,850,000	13,682,000
Non-current liabilities:
Term loan, net of current portion and deferred financing costs	5,883,000	7,566,000
Line of credit	0	1,500,000
Notes payable, net of deferred financing costs	4,129,000	0
Deferred revenues, less current portion	190,000	173,000
Total non-current liabilities	10,202,000	9,239,000
Total liabilities	22,052,000	22,921,000
Commitments and contingencies – Note 8
Stockholders’ equity:
Common stock, $0.01 par value per share, 85,000,000 shares authorized; 4,265,821 and 3,929,446 shares issued and outstanding, respectively	43,000	39,000
Additional paid in capital	137,588,000	134,474,000
Accumulated deficit	(123,717,000)	(115,699,000)
Total stockholders’ equity	13,914,000	18,814,000
Total liabilities and stockholders’ equity	$ 35,966,000	$ 41,735,000

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Oct. 31, 2024
Insider Trading Arr Line Items
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 2 - Summary of Significant Accounting Policies 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-11-01	Oct. 31, 2024
Revenue, Remaining Performance Obligation, Percentage	46.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	12 months

Note 6 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Note 6 - Income Taxes (Details Textual) - USD ($)	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Jan. 31, 2024
Income Tax Expense (Benefit)	$ (0)	$ (120,000)	$ (0)	$ (59,000)
Effective Income Tax Rate Reconciliation, Percent			0.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			24.00%
Unrecognized Tax Benefits	$ 346,000		$ 346,000		$ 340,000

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Note 1 - Basis of Presentation (Details Textual)			9 Months Ended
Note 1 - Basis of Presentation (Details Textual)	Oct. 04, 2024	Jan. 31, 2024 USD ($)	Oct. 31, 2024 USD ($)
Number of Operating Segments			1
Number of Reportable Segments			1
Long-Term Debt		$ 9,066,000	$ 8,133,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	15
Adjustments to Additional Paid in Capital, Stock Split		(551,000)
Term Loan [Member]
Long-Term Debt			12,300,000
Long-Term Debt, Current Maturities		$ 1,500,000	$ 2,250,000

Use of Estimates, Policy [Policy Text Block]

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Significant Accounting Policies (Policies)

9 Months Ended

Oct. 31, 2024

Accounting Policies [Abstract]

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The acquisition earnout liability transferred out of Level 3 as of April 30, 2024.

The table below provides information on the fair value of our liabilities on a recurring basis:

Quoted

Significant

Prices in

Other

Significant

Active

Observable

Unobservable

Total Fair

Markets

Inputs

Value

(Level 1)

(Level 2)

(Level 3)

At January 31, 2024

Acquisition earnout liability (1)

1,794,000

—

1,794,000

(1)

On March 27, 2024, the Company issued the shares of its common stock owed as part of the acquisition earnout liability related to the acquisition of Avelead Consulting, LLC (“Avelead”). The remaining obligation related to the acquisition earnout liability is to be settled in cash (refer to Note 3 – Business Combinations for more information). At that time, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was transferred out. As of that date, the Company recorded a valuation adjustment of $159,000 using the value of the shares issued adjusted for a discount for lack of marketability. See the table below for the roll-forward of values including the amount transitioned out of Level 3.

The table below provides the Level 3 roll-forward on the fair value of our acquisition earnout liability for the nine months ended October 31, 2024. There was no Level 3 roll-forward activity for the three months ended October 31, 2024.

	Nine-months ended
	October 31, 2024
Beginning balance	$	1,794,000
Settlement – common stock		(690,000	)
Settlement – cash		(447,000	)
Realized loss		159,000
Transfer out		(817,000	)
Ending balance	$	—

The value of the Company’s acquisition earnout liability at October 31, 2024, represents the remaining cash obligation of $377,000. The Company reached an agreement with the former owners of Avelead to settle the cash obligation by making periodic payments. The remaining outstanding amounts were originally contractually due by October 31, 2024.

The fair value of the Company’s term loan under its Second Amended and Restated Loan and Security Agreement (as amended and modified, the “Second Amended and Restated Loan Agreement”) was determined through an analysis of the interest rate spread from the date of closing the loan ( August 2021) to the date of the most recent balance sheets, October 31, 2024 and January 31, 2024. The term loan bears interest at a per annum rate equal to the Prime Rate (as published in The Wall Street Journal) plus 1.5%, with a Prime “floor” rate of 3.25%. The prime rate is variable and, thus accommodates changes in the market interest rate. However, the interest rate spread (the 1.5% added to the Prime Rate) is fixed. We estimated the impact of the changes in the interest rate spread by analogizing the effect of the change in the published “Corporate Bond Rates,” reduced for any changes in the market interest rate. This provided us with an estimated change to the interest rate spread of approximately 0.5% from the date we entered the Second Amended and Restated Loan Agreement for the term loan. The fair value of the Company's term loan as of October 31, 2024 and January 31, 2024, was estimated to be $7,821,000 and $8,807,000, respectively, or a discount to book value of $179,000 and $193,000, respectively. The fair value of the Company's term loan represents a Level 2 measurement.

The estimated fair value of the Company’s notes payable under its private placement notes payables was determined through an analysis of the interest rate spread from the date of closing of the private placement ( February 7, 2024) to the date of the most recent balance sheet, October 31, 2024. The Company estimated the yield of a 30-month treasury by interpolating the yields of the 1-month through 10-year treasury yields on February 7, 2024 (the “Issuance Date”) and the measurement date. A High Yield Index Option Adjusted Spread, as published by the Federal Reserve Bank of St. Louis, for the same dates was added to the treasury yield spread to calculate a High-Yield Spread Adjusted 30-Month Rate. This provided an estimated change to the effective interest rate spread of approximately 0.98% less than the Issuance Date. The fair value of the Company's notes payable as of October 31, 2024, was estimated to be $4,096,000, or a discount to book value of $33,000. The fair value of the Company's notes payable represents a Level 2 measurement.

The estimated fair value of the warrant liability is calculated using a Black-Scholes pricing model. The model input uses the warrant strike prices of $5.70 and $5.85, market prices on the measurement dates ($5.10 as of February 7, 2024, $4.50 as of April 30, 2024, and $4.95 as of May 7, 2024) plus assumptions and model inputs for expected term, historical volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). The warrants carry a term of 48 months and the Company assumes they are held until expiration. The risk-free rate was determined from the U.S. Treasury published daily treasury yields corresponding with the remaining expected term which ranged between 4% - 5%. The Company’s common stock volatility was estimated between 91% - 92% utilizing its historical average closing price for preceding trading days equal to expected term remaining.

Using this methodology, the Company recorded an opening warrant liability of $881,000 as of February 7, 2024. Re-measurements as of April 30, 2024 and May 7, 2024 are reflected under the “Valuation adjustments” header on the condensed consolidated statement of operations as a valuation gain of $44,000 for the nine months ending October 31, 2024. There was no valuation adjustment recorded in the three months ended October 31, 2024. As of May 7, 2024, the Company had eliminated the potential cash settlement feature that caused liability accounting ensuring the warrants will be settled with shares, and accordingly, the warrants met the criteria for equity classification and reclassified $837,000 to paid in capital after a final re-measurement.

Revenue [Policy Text Block]

Revenue Recognition

We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model, through the Company’s direct sales force or through third-party resellers. Licensed, locally-installed software customers on a perpetual model utilize the Company’s support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization of the applications, as well as audit services and consulting services.

We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, under the core principle of recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Certain contracts may include aspects of variable consideration as it relates to performance guarantees and service level agreements. Significant judgment is required to determine the standalone selling price (“SSP”) for each performance obligation, impact of variable consideration on total contract price, the amount allocated to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange for the related product and/or service.

Disaggregation of Revenue

The following table provides information about disaggregated revenue by type and nature of revenue stream:

	Three Months Ended				Nine Months Ended
	October 31, 2024		October 31, 2023		October 31, 2024		October 31, 2023
Over time revenue	$	4,419,000	$	6,133,000	$	13,091,000	$	17,161,000
Point in time revenue		—		—		135,000		74,000
Total revenue	$	4,419,000	$	6,133,000	$	13,226,000	$	17,235,000

The Company includes revenue categories of (i) SaaS, (ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses as point in time revenue.

Contract Receivables and Deferred Revenues

The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. The Company’s contract receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. During the three and nine months ended October 31, 2024, the Company recognized approximately $1,253,000 and $5,878,000, respectively, in revenue from deferred revenues outstanding as of January 31, 2024. Revenue allocated to remaining performance obligations was $30,068,000 as of October 31, 2024, of which the Company expects to recognize approximately 46% over the next 12 months and the remainder thereafter.

Deferred costs (costs to fulfill a contract and contract acquisition costs)

The Company defers the direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill a contract. These deferred costs will be amortized on a straight-line basis over the period of expected benefit which is the contractual term. As of October 31, 2024 and January 31, 2024, the Company had deferred costs of $68,000 and $77,000, respectively, net of accumulated amortization of $147,000 and $102,000, respectively. Amortization expense of these costs was $44,000 and $59,000 for the nine months ended October 31, 2024 and 2023, respectively, and is included in cost of SaaS in the condensed consolidated statements of operations. For the three months ended October 31, 2024 and 2023, the Company had amortization expense of $11,000 and $24,000, respectively.

Contract acquisition costs, which consist of sales commissions paid or payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs is expected to be one year or less.

As of October 31, 2024 and January 31, 2024, deferred commission costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $1,157,000 and $1,461,000, respectively. Amortization expense associated with deferred sales commissions, which is included in selling, general and administrative expense in the condensed consolidated statements of operations, was $141,000 and $129,000 for the three months ended October 31, 2024 and 2023, respectively. For the nine months ended October 31, 2024 and 2023, the amortization expense associated with deferred sales commissions was $450,000 and $383,000, respectively. For the three and nine months ended October 31, 2024, the Company recorded an impairment of $93,000 for deferred commission costs. For the three and nine months ended October 31, 2023, the Company recorded an impairment of $35,000 for deferred commission costs.

Allowance for Credit Losses

The Company estimates current expected credit losses based on historical credit loss rates and applied an increase to account for future economic conditions. The changes in the Company’s allowance for credit losses is as follows:

		*January 31, 2024*				*CECL Adoption*				*Provision adjustments*				*Write-offs & Recoveries*				*October 31, 2024*
Allowance for credit losses		$	86,000			$	—				(58,000	)			31,000			$	59,000

		January 31, 2023				CECL Adoption				Provision adjustments				Write-offs & Recoveries				October 31, 2023
Allowance for credit losses		$	132,000			$	(36,000	)		$	—			$	—			$	96,000

Share-Based Payment Arrangement [Policy Text Block]

Equity Awards

The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period, and forfeitures are recognized as incurred. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the entity had paid cash for the goods or services. The Company incurred total compensation expense related to share-based awards for the three and nine months ended October 31, 2024, of $451,000 and $1,483,000 respectively, net of $41,000 and $109,000, respectively, of capitalized non-employee stock compensation, compared to share-based compensation expense of $517,000 and $1,626,000, respectively, net of $60,000 and $176,000, respectively, of capitalized non-employee stock compensation, for the three and nine months ended October 31, 2023.

The fair value of stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Future grants of equity awards accounted for as share-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards.

The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market closing price per share on the grant date. For the three and nine months ended October 31, 2024, the Company issued 333 and 181,321 shares of restricted common stock, respectively, compared to 2,999 and 92,562 shares of restricted common stock for the three and nine months ended October 31, 2023, respectively. The Company expenses the compensation cost of these awards as the restriction period lapses.

Market-Based Awards

For awards with a market condition, the Company adjusts the grant date fair value for the condition. The Company used separate Monte Carlo valuation models, as of the grant date, to determine the expected length and fair value of this particular award. Both models used the Company's historical equity volatility, current stock price, and hurdle target price for vesting. The service period model also included an assumption for the Company's 10-year normalized risk-free rate. The associated compensation expense is recognized provided the service condition is provided regardless of whether the market condition is satisfied.

On July 18, 2024, the Company, as a component of the Board awards discussed above, executed a Restricted Stock Agreement (the “Restricted Stock Agreement”) to issue 13,333 shares of restricted stock with a market vesting condition to a member of the Board. The shares will vest on the date the stock closes at a fair market value of at least $26.25 per share.

On September 4, 2024, the Restricted Stock Agreement was amended to rescind 6,666 shares of restricted stock. The remaining shares will vest in full upon the stock closing at a fair market value of at least $26.25 per share, but no earlier than July 18, 2025. The award modification was reevaluated using the same Monte Carlo valuation model and input as the original grant with a change to account for the minimum vesting period. The impacts of the modification were immaterial.

Derivatives, Policy [Policy Text Block]

Warrants

The Company reviews the specific terms for its warrants and applies the authoritative FASB guidance under ASC topics 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) to account for the warrants as either equity-classified or liability-classified instruments. This review identifies if the warrants are freestanding financial instruments under ASC 480, should be defined as a liability under ASC 480, and whether the warrants meet all requirements of ASC 815 to be classified as equity, including whether the warrants are indexed to the Company’s own common stock, if there are conditions where warrant holders could potentially require “net cash settlement” in a circumstance that would be outside of the Company’s control, among other conditions for equity classification. This assessment requires the use of professional judgment and is conducted at the time of warrant issuance plus as of each subsequent quarterly period end date while the warrants are outstanding.

For the issued or modified warrants that qualify for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated Statements of Operations as "valuation adjustments." The fair value of the warrants is estimated using a Black-Scholes pricing model.

Income Tax, Policy [Policy Text Block]

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. Refer to Note 6 – Income Taxes for further details.

The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. The Company believes it has appropriately accounted for any uncertain tax positions as of October 31, 2024.

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Common Share

The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock.

The Company’s warrants, unvested restricted stock awards, and options are considered non-participating securities because holders are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term or while unexercised. Diluted EPS for the Company’s common stock is computed using the treasury stock method.

The following is the calculation of the basic and diluted net loss per share of common stock for the three and nine months ended October 31, 2024 and 2023:

	*Three Months Ended*						*Nine Months Ended*
	*October 31, 2024*			*October 31, 2023*			*October 31, 2024*			*October 31, 2023*
Basic and diluted loss per share:
Net loss	$	(2,476,000	)	$	(11,911,000	)	$	(8,018,000	)	$	(17,327,000	)
Basic and diluted net loss per share of common stock	$	(0.61	)	$	(3.15	)	$	(2.01	)	$	(4.61	)
Weighted average shares outstanding – basic and diluted (1)(2)		4,055,268			3,780,689			3,981,406			3,756,420

(1)	Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of October 31, 2024 and 2023, there were 220,327 and 132,013 unvested restricted shares of common stock outstanding, respectively.

(2)	Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three and nine months ended October 31, 2024, diluted earnings per share excludes 4,396 outstanding stock options, 220,327 unvested restricted shares of common stock, and 237,027 shares of common stock issuable through the exercise of warrants. For the three and nine months ended October 31, 2023, diluted earnings per share excludes 27,919 outstanding stock options and 132,013 unvested restricted shares of common stock.

Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]

Restructuring

On October 16, 2023, the Company announced it was executing a strategic restructuring (the "Strategic Restructuring") designed to reduce expenses while maintaining the Company’s ability to expand its SaaS business. The Strategic Restructuring initiatives included a reduction in force, resulting in the termination of 26 employees, or approximately 24% of the Company’s workforce. To execute the Strategic Restructuring, the Company incurred one-time restructuring costs associated with the workforce reduction of $759,000, and the Company has recognized all expenses associated with the Strategic Restructuring as of the end of fiscal 2023. The costs pertain to severance and other employee termination-related costs and various professional fees the Company required to assist with execution of the Strategic Restructuring. For the nine months ended October 31, 2024, there were no costs incurred or accrued related to the Strategic Restructuring. The following is a reconciliation of the Strategic Restructuring liability reflected on the Company’s condensed consolidated balance sheet under “accrued expenses.”

	(in thousands)
										*As of October 31, 2024*
	*Accrued Balance as of*		*2024*		*2024*			*Accrued Balance as of*		*Total Costs*		*Total*
	*January 31, 2024*		*Expenses to Date*		*Cash Payments*			*October 31, 2024*		*Incurred to Date*		*Expected Costs*
Severance expense
Cost of sales	$	—	$	—	$	—		$	—	$	154	$	154
Selling, general, and administrative		74		—		(74	)		—		350		350
Research and development		—		—		—			—		227		227
Total severance expense	$	74	$	—	$	(74	)	$	—	$	731	$	731
Professional fees		—		—		—			—		28		28
Total	$	74	$	—	$	(74	)	$	—	$	759	$	759

	(in thousands)

	Accrued Balance as of		2023		2023		Accrued Balance as of
	January 31, 2023		Expenses to Date		Cash Payments		October 31, 2023
Severance expense
Cost of sales	$	—	$	154	$	—	$	154
Selling, general, and administrative		—		350		—		350
Research and development		—		227		—		227
Total severance expense	$	—	$	731	$	—	$	731
Professional fees		—		18		—		18
Total	$	—	$	749	$	—	$	749

Noncash Investing and Financing Activities [Policy Text Block]

Non-Cash Items

For the three and nine months ended October 31, 2024 and 2023, the Company recorded a change in capitalized software purchased with stock, totaling $41,000 and $109,000, and $60,000 and $176,000, respectively, as non-cash items as it relates to non-cash investing activities in the condensed consolidated statements of cash flow.

For the nine months ended October 31, 2024, the Company settled the second year acquisition earnout liability in connection with the Avelead acquisition with the issuance of common shares in the amount of $690,000, issued warrants in the amount of $881,000 as debt discounts, settled the warrant liability of $837,000 with an equity based warrant, deferred financing costs for the Notes (refer to Note 5 – Debt) in the amount of $20,000 that was capitalized and paid in fiscal year 2023, and professional fees for the Common Stock Private Placement (refer to Note 7 – Equity) in the amount of $4,000, respectively, as non-cash items as it relates to financing activities in the condensed consolidated statements of cash flows. The Company did not have any similar non-cash financing activities in the nine months ended October 31, 2023.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves guidance around the disclosures about a public entity’s reportable segments and additional details about a reportable segment’s expenses. ASU 2023-07 is effective for all public entities for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company’s adoption of ASU 2023-07 will be effective in the annual report for the fiscal year ending January 31, 2025. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhance the transparency and decision usefulness of income tax disclosures. For public entities, ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which improves financial reporting by requiring public entities to disclose additional information about specific expense categories in the notes of the financial statements at interim and annual reporting period. ASU 2024-03 is effective for all public entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The adoption of this ASU is expected to improve reporting and does not have an overall material impact on our financial disclosures.

Note 10 - Goodwill and Intangible Assets (Details Textual)	3 Months Ended		9 Months Ended
	Oct. 31, 2024 USD ($)	Oct. 31, 2023 USD ($)	Oct. 31, 2024 USD ($)	Oct. 31, 2023 USD ($)
Number of Reporting Units			1
Goodwill, Impairment Loss	$ 0	$ 9,813,000	$ 0	$ 9,813,000
Impairment, Long-Lived Asset, Held-for-Use	$ 0	$ 963,000	$ 0	$ 963,000

Note 2 - Summary of Significant Accounting Policies 1 (Details Textual)						3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 04, 2024 $ / shares shares	Jul. 18, 2024 $ / shares shares	May 07, 2024 USD ($)	Mar. 27, 2024 USD ($)	Oct. 16, 2023 USD ($)	Oct. 31, 2024 USD ($) shares	Jul. 31, 2024 USD ($)	Oct. 31, 2023 USD ($) shares	Oct. 31, 2024 USD ($) shares	Oct. 31, 2023 USD ($) shares	Jan. 31, 2023 USD ($)	Apr. 30, 2024	Feb. 07, 2024 USD ($)	Jan. 31, 2024 USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				$ 159,000
Business Combination, Contingent Consideration, Liability, Current						$ 377,000			$ 377,000					$ 1,794,000
Contract with Customer, Liability, Revenue Recognized						1,253,000			5,878,000
Revenue, Remaining Performance Obligation, Amount						30,068,000			30,068,000
Deferred Costs						68,000			68,000					77,000
Accumulated Amortization of Other Deferred Costs						147,000			147,000					102,000
Amortization of Deferred Charges						11,000		$ 24,000	44,000	$ 59,000
Deferred Commission Costs Paid and Payable						1,157,000			1,157,000					1,461,000
Amortization of Deferred Sales Commissions						141,000		129,000	450,000	383,000
Deferred Sales Commissions, Impairment Loss						93,000		35,000	93,000	35,000
Share-Based Payment Arrangement, Expense						451,000		517,000	$ 1,483,000	$ 1,626,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares									220,327	132,013
Restructuring and Related Cost, Number of Positions Eliminated					26
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent					24.00%
Restructuring Costs					$ 759,000		$ 0
Stock Issued						$ 41,000		$ 60,000	$ 109,000	$ 176,000
Professional Fees, Noncash									$ 4,000
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares						4,396		27,919	4,396	27,919
Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares						220,327		132,013	220,327	132,013
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares						237,027			237,027
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) \| shares						333		2,999	181,321	92,562
Restricted Stock [Member] \| Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) \| shares		13,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures (in shares) \| shares	6,666
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Payment Arrangement, Expense						$ 41,000		$ 60,000	$ 109,000	$ 176,000
Common Stock Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings						$ 0			$ 44,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3			$ 837,000
Minimum [Member] \| Restricted Stock [Member] \| Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Price (in dollars per share) \| $ / shares	$ 26.25	$ 26.25
Common Stock Warrant [Member]
Warrants and Rights Outstanding													$ 881,000
Measurement Input, Exercise Price [Member] \| Common Stock Warrant [Member]
Warrants and Rights Outstanding, Measurement Input			4.95									4.5	5.1
Measurement Input, Exercise Price [Member] \| Common Stock Warrant [Member] \| Minimum [Member]
Warrants and Rights Outstanding, Measurement Input						5.7			5.7
Measurement Input, Exercise Price [Member] \| Common Stock Warrant [Member] \| Maximum [Member]
Warrants and Rights Outstanding, Measurement Input						5.85			5.85
Measurement Input, Risk Free Interest Rate [Member] \| Common Stock Warrant [Member] \| Minimum [Member]
Warrants and Rights Outstanding, Measurement Input						0.04			0.04
Measurement Input, Risk Free Interest Rate [Member] \| Common Stock Warrant [Member] \| Maximum [Member]
Warrants and Rights Outstanding, Measurement Input						0.05			0.05
Measurement Input, Price Volatility [Member] \| Common Stock Warrant [Member] \| Minimum [Member]
Warrants and Rights Outstanding, Measurement Input						0.91			0.91
Measurement Input, Price Volatility [Member] \| Common Stock Warrant [Member] \| Maximum [Member]
Warrants and Rights Outstanding, Measurement Input						0.92			0.92
Term Loan and Revolving Line of Credit [Member]
Debt Instrument, Basis Spread on Variable Rate									1.50%
Debt Instrument, Basis Rate Floor									3.25%
Debt Instrument, Increase (Decrease) in Basis Spread on Variable Rate									0.50%
Debt Instrument, Unamortized Discount						$ 179,000			$ 179,000					193,000
Term Loan and Revolving Line of Credit [Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Instrument, Fair Value Disclosure						7,821,000			$ 7,821,000					$ 8,807,000
Private Placement Notes [Member]
Debt Instrument, Increase (Decrease) in Basis Spread on Variable Rate									0.98%
Debt Instrument, Unamortized Discount						33,000			$ 33,000
Private Placement Notes [Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Instrument, Fair Value Disclosure						4,096,000			4,096,000
Unsecured Subordinated Promissory Notes [Member]
Debt Instrument, Fair Value Disclosure						3,538,000			3,538,000
Debt Instrument, Unamortized Discount						862,000			862,000
Payments of Debt Issuance Costs											$ 20,000
Avelead Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Current						$ 377,000			377,000
Avelead Acquisition [Member] \| Common Stock [Member] \| Second Earnout [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable									690,000
Avelead Acquisition [Member] \| Warrant 1 [Member] \| Second Earnout [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable									$ 881,000

Note 10 - Goodwill and Intangible Assets - Summary of Goodwill (Details) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Balance			$ 13,276,000	$ 23,089,000
Impairment	$ 0	$ (9,813,000)	0	(9,813,000)
Balance	$ 13,276,000	$ 13,276,000	$ 13,276,000	$ 13,276,000

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Net loss per common share – basic and diluted (in dollars per share)

Note 2 - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details) - USD ($)

3 Months Ended

9 Months Ended

Oct. 31, 2024

Jul. 31, 2024

Apr. 30, 2024

Oct. 31, 2023

Jul. 31, 2023

Apr. 30, 2023

Oct. 31, 2024

Oct. 31, 2023

Net loss

$ (2,476,000)

$ (2,803,000)

$ (2,739,000)

$ (11,911,000)

$ (2,515,000)

$ (2,901,000)

$ (8,018,000)

$ (17,327,000)

$ (0.61)

$ (3.15)

$ (2.01)

$ (4.61)

Weighted average number of common shares – basic and diluted (in shares)

^[1],[2]

4,055,268

3,780,689

3,981,406

3,756,420

[1]

[2]

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Wyche Tee Green III [Member]

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	0
Balance (in shares) at Jan. 31, 2023					3,837,560
Balance (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	$ 0	$ 0	$ 36,000	$ 36,000
Balance at Jan. 31, 2023					$ 38,000	$ 132,511,000	$ (97,038,000)	$ 35,511,000
Restricted stock issued (in shares)					79,061
Restricted stock issued					$ 1,000	(1,000)	0	0
Restricted stock forfeited (in shares)					(1,893)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(5,888)
Surrender of shares					$ 0	(179,000)	0	(179,000)
Share-based compensation					0	595,000	0	595,000
Net loss					$ 0	0	(2,901,000)	(2,901,000)
Balance (in shares) at Apr. 30, 2023					3,908,840
Balance at Apr. 30, 2023					$ 39,000	132,926,000	(99,903,000)	33,062,000
Balance (in shares) (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	0
Balance (in shares) at Jan. 31, 2023					3,837,560
Balance (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	$ 0	$ 0	$ 36,000	$ 36,000
Balance at Jan. 31, 2023					$ 38,000	132,511,000	(97,038,000)	35,511,000
Net loss								(17,327,000)
Balance (in shares) at Oct. 31, 2023					3,919,345
Balance at Oct. 31, 2023					$ 39,000	134,041,000	(114,329,000)	19,751,000
Balance (in shares) at Apr. 30, 2023					3,908,840
Balance at Apr. 30, 2023					$ 39,000	132,926,000	(99,903,000)	33,062,000
Restricted stock issued (in shares)					25,714
Restricted stock issued					$ 0	0	0	0
Restricted stock forfeited (in shares)					(5,133)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(3,337)
Surrender of shares					$ 0	(73,000)	0	(73,000)
Share-based compensation					0	630,000	0	630,000
Net loss					$ 0	0	(2,515,000)	(2,515,000)
Balance (in shares) at Jul. 31, 2023					3,926,084
Balance at Jul. 31, 2023					$ 39,000	133,483,000	(102,418,000)	31,104,000
Restricted stock issued (in shares)					11,736
Restricted stock issued					$ 0	0	0	0
Restricted stock forfeited (in shares)					(15,940)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(2,535)
Surrender of shares					$ 0	(19,000)	0	(19,000)
Share-based compensation					0	577,000	0	577,000
Net loss					$ 0	0	(11,911,000)	(11,911,000)
Balance (in shares) at Oct. 31, 2023					3,919,345
Balance at Oct. 31, 2023					$ 39,000	134,041,000	(114,329,000)	19,751,000
Balance (in shares) at Jan. 31, 2024					3,929,446
Balance at Jan. 31, 2024					$ 39,000	134,474,000	(115,699,000)	18,814,000
Restricted stock issued (in shares)					81,000
Restricted stock issued					$ 1,000	(1,000)	0	0
Restricted stock forfeited (in shares)					(3,224)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(9,273)
Surrender of shares					$ 0	(67,000)	0	(67,000)
Share-based compensation					$ 0	529,000	0	529,000
Issuance of common stock (in shares)					123,502
Issuance of common stock					$ 1,000	769,000	0	770,000
Offering expenses					0	(4,000)	0	(4,000)
Net loss					$ 0	0	(2,739,000)	(2,739,000)
Balance (in shares) at Apr. 30, 2024					4,121,451
Balance at Apr. 30, 2024					$ 41,000	135,700,000	(118,438,000)	17,303,000
Balance (in shares) at Jan. 31, 2024					3,929,446
Balance at Jan. 31, 2024					$ 39,000	134,474,000	(115,699,000)	18,814,000
Net loss								(8,018,000)
Balance (in shares) at Oct. 31, 2024					4,265,821
Balance at Oct. 31, 2024					$ 43,000	137,588,000	(123,717,000)	13,914,000
Balance (in shares) at Apr. 30, 2024					4,121,451
Balance at Apr. 30, 2024					$ 41,000	135,700,000	(118,438,000)	17,303,000
Restricted stock issued (in shares)					113,769
Restricted stock issued					$ 1,000	(1,000)	0	0
Restricted stock forfeited (in shares)					(18,817)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(3,452)
Surrender of shares					$ 0	(10,000)	0	(10,000)
Share-based compensation					0	571,000	0	571,000
Net loss					$ 0	0	(2,803,000)	(2,803,000)
Cashless exercise of warrants (in shares)					7,317
Cashless exercise of warrants					$ 0	0	0	0
Warrant liability reclassification					$ 0	837,000	0	837,000
Balance (in shares) at Jul. 31, 2024					4,220,268
Balance at Jul. 31, 2024					$ 42,000	137,097,000	(121,241,000)	15,898,000
Restricted stock issued (in shares)					54,801
Restricted stock issued					$ 1,000	(1,000)	0	0
Restricted stock forfeited (in shares)					(8,445)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(803)
Surrender of shares					$ 0	0	0	0
Share-based compensation					0	492,000	0	492,000
Net loss					$ 0	0	(2,476,000)	(2,476,000)
Balance (in shares) at Oct. 31, 2024					4,265,821
Balance at Oct. 31, 2024					$ 43,000	$ 137,588,000	$ (123,717,000)	$ 13,914,000

Note 7 - Equity (Details Textual) - USD ($)				3 Months Ended
Note 7 - Equity (Details Textual) - USD ($)	May 24, 2024	Feb. 06, 2024	Jun. 28, 2023	Apr. 30, 2024	Jun. 13, 2024
The 2024 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)					449,260
180 Consulting [Member]
Stock Issued During Period, Shares, New Issues (in shares)	37,647		26,275
Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares)		17,543
Sale of Stock, Price Per Share (in dollars per share)		$ 5.7
Sale of Stock, Consideration Received on Transaction		$ 100,000
Net Proceeds from Issuance of Private Placement				$ 77,000
Proceeds from Issuance of Private Placement				81,000
Payments of Stock Issuance Costs				$ 4,000

Note 5 - Debt - Schedule of Adjusted EBITDA Ratio (Details)	3 Months Ended
	Jan. 31, 2026	Oct. 31, 2025	Jul. 31, 2025	Apr. 30, 2025
Forecast [Member]
Adjusted EBITDA ratio	2	2.5	3	3.5

Note 3 - Business Combination (Details Textual) - USD ($)		3 Months Ended	9 Months Ended
	Mar. 27, 2024	Oct. 31, 2024	Oct. 31, 2024	Jan. 31, 2024
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.01	$ 0.01	$ 0.01
Business Combination, Contingent Consideration, Liability, Current		$ 377,000	$ 377,000	$ 1,794,000
Avelead Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	105,958
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01
Payments to Acquire Businesses, Gross		200,000	887,000
Business Combination, Contingent Consideration, Liability, Current		$ 377,000	$ 377,000
Avelead Acquisition [Member] \| Earn Out Liability [Member]
Business Combination, Contingent Consideration, Liability				$ 1,794,000

Note 9 - Related Party Transactions - Schedule of Related Party Transactions (Details)

Feb. 07, 2024

USD ($)

Wyche Tee Green III [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]

$ 1,000,000

^[1]

Matthew Etheridge [Member]

59,829

^[1]

Matthew Etheridge [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]

$ 1,000,000

Jonathan R Phillips [Member]

61,403

Jonathan R Phillips [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]

$ 50,000

^[2]

Justin J Ferayorni [Member]

2,991

^[2]

Justin J Ferayorni [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]

$ 500,000

^[3]

29,914

^[3]

[1]	The securities held in the account of 121G, LLC (“121G”) may be deemed to be beneficially owned by Wyche “Tee” Green, III, the managing member of 121G. Mr. Green serves as Executive Chairman of the Company and is a member of the Company’s Board of Directors.
[2]	Mr. Phillips is a member of the Company’s Board of Directors.
[3]	The securities held in the account of The Ferayorni Family Trust may be deemed to be beneficially owned by Justin J. Ferayorni as co-trustee of The Ferayorni Family Trust. Mr. Ferayorni is a member of the Company’s board of directors.

Note 7 - Equity

9 Months Ended

Oct. 31, 2024

Equity [Text Block]

NOTE 7 — EQUITY

Common Stock Private Placement

On February 6, 2024, the Company completed the sale of 17,543 shares of the Company’s common stock to Matthew W. Etheridge at a purchase price of $5.70 per share for an aggregate purchase price of $100,000 (the “Common Stock Private Placement”). Mr. Etheridge became a director of the Company subsequent to the closing of the Debt Private Placement.

The common stock described above was offered in a private placement under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and has not been registered under the Securities Act or applicable state securities laws. Accordingly, such common stock may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements and in accordance with applicable state securities laws. The common stock was offered and sold to an “accredited investor” as that term is defined in Rule 501(a) under the Securities Act.

The Company allocated the total proceeds of the Common Stock Private Placement across the underlying components. As a result, $77,000 of net proceeds, comprised of $81,000 of the proceeds less $4,000 of issuance costs, were recorded for the Common Stock Private Placement as equity.

Registration of Shares Issued to 180 Consulting

On June 28, 2023, the Company filed a Registration Statement on Form S-3 (Registration No. 333-272993) for purpose of registering for resale 26,275 shares of common stock issued to 180 Consulting, LLC (“180 Consulting”). The Registration Statement was declared effective by the SEC on July 10, 2023.

On May 7, 2024, the Company filed a Registration Statement on Form S-3 (Registration No. 333-279190), as amended by that certain Pre-Effective Amendment No. 1 to Form S-3 filed on May 24, 2024, for purpose of registering for resale 37,647 shares of common stock issued to 180 Consulting. The Registration Statement was declared effective by the SEC on June 10, 2024.

2024 Omnibus Incentive Compensation Plan

At the 2024 Annual Meeting of Stockholders held on June 13, 2024, the Company’s stockholders approved the Streamline Health Solutions, Inc. 2024 Omnibus Incentive Compensation Plan (the “2024 Plan”). The 2024 Plan replaced the Streamline Health Solutions, Inc. Third Amended and Restated 2013 Stock Incentive Plan (as amended, the “2013 Plan”). The Compensation Committee of the Board of Directors administers the 2024 Plan and approves the grant and terms of awards (consistent with the terms of the 2024 Plan).

The 2024 Plan permits the grant of any or all of the following types of awards to grantees: stock options, including non-qualified options and incentive stock options (“ISOs”); stock appreciation rights (“SARs”); restricted stock; deferred stock and restricted stock units; performance units and performance shares; dividend equivalents; and other stock-based awards. Eligible grantees include employees, officers, non-employee consultants and non-employee directors of the Company and its affiliates. A total of 449,260 shares of common stock were initially available for issuance under the 2024 Plan.

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Note 10 - Goodwill and Intangible Assets

9 Months Ended

Oct. 31, 2024

Goodwill and Intangible Assets Disclosure [Text Block]

NOTE 10 - GOODWILL AND INTANGIBLE ASSETS

Goodwill represents the excess cost over fair value of the net assets of acquired businesses and is not amortized. The Company performs an impairment assessment of goodwill annually during the fourth quarter of its fiscal year with a valuation date of November 1, or more frequently if a triggering event occurs.

The Company’s intangible assets consist of client relationships, acquired and developed technology, and trade names. These assets are recorded at cost, less accumulated amortization and impairment, if any. All the Company’s intangible assets are definite lived and amortized on a straight-line basis over their estimated useful lives. Subsequent testing of intangible assets is conducted when a triggering event occurs that would indicate impairment may exist.

During the quarter ended October 31, 2024, the Company's market capitalization fell below the Company's carrying value of equity for a prolonged period of time (the “2024 Triggering Event”). Based on the 2024 Triggering Event, the Company identified indicators of possible impairment and initiated testing using a valuation date of October 31, 2024. The impairment tests were conducted under guidance of ASC Topic 360, Impairment and Disposal of Long-Lived Assets (“ASC 360”) for certain long-lived assets, including capitalized contract costs, developed technology, client relationships and trade names, and in accordance with ASC Topic 350, Intangibles – Goodwill and Other (“ASC 350”) with respect to the reporting unit’s goodwill.

In October 2023, the Company was notified by a legacy client of its intent to not renew its contract as of its end date on December 31, 2023. The Company also announced the acceleration of its Strategic Restructuring that was designed to reduce costs while maintaining the Company’s ability to expand its SaaS business. Both the client termination and the execution of the Strategic Restructuring were announced on October 16, 2023. Following these announcements, the Company’s share price declined significantly (collectively, the “2023 Triggering Events”). Based on the 2023 Triggering Events, the Company identified indicators of possible impairment and initiated testing using a valuation date of October 31, 2023. The impairment tests were conducted under guidance of ASC 360 for certain long-lived assets, including capitalized contract costs, developed technology, client relationships and trade names, and in accordance with ASC 350.

Goodwill

The Company has one reporting unit for purposes of evaluation of goodwill. Impairment testing was performed under the guidance of ASC 350 and utilized a discounted debt-free net cash flow (“DCF”) method under the income approach and the market capitalization method (“MCM”) under the market approach. The sum of the weighted values of each method was used to derive the fair value of the Company’s equity.

The MCM calculates the aggregate market value of the Company based on the total number of shares outstanding and the current market price of the shares as of the valuation date. Data on similar mergers and acquisitions within healthcare technology are observed to determine control premium that represents a stock premium percentage offered by an acquirer to a public company. The control premium applied to the aggregate market value represents MCM calculated fair value.

The DCF incorporates the use of projected financial information and a discount rate using a weighted average cost of capital with cost of equity estimated based on the capital asset pricing model. The cash-flow projections are based on financial forecasts developed by management that include forecasts of future operating results based on internal budgets and strategic plans to invest in working capital to support anticipated revenue growth. External factors and business conditions are considered by management when setting the long-term growth rates. The selected discount rate considers the risk and nature of the reporting unit’s cash flows and the rates of return market participants would require to invest their capital in the Company.

Based on the impairment test following the 2024 Triggering Event, the Company concluded that its goodwill was not impaired as of October 31, 2024. Based on the impairment test following the 2023 Triggering Events, the Company concluded that its goodwill was impaired as of October 31, 2023, based on the weighted combination of the DCF and MCM value estimates which resulted in a calculated fair value lower than the equity carrying value. The Company recorded an impairment of goodwill in the amount of $9,813,000 reported as “Goodwill Impairment” on its Condensed Consolidated Statement of Operations for the nine-month period ended October 31, 2023.

The changes in the carrying amount of goodwill were as follows for the nine-month period ended October 31, 2023:

	Nine Months Ended
	October 31, 2023
Balance as of January 31, 2023	$	23,089,000
Impairment		(9,813,000	)
Balance as of October 31, 2023	$	13,276,000

Intangible Assets

ASC 360 defines a multi-step process to test long-lived assets, including intangible assets, for recoverability that if failed would indicate impairment. First, the Company must consider whether indicators of impairment of long-lived assets are present, which the Company determined the 2023 Triggering Events in conjunction with preparation of its financial statements for the three and nine months ended October 31, 2023, provided such indication.

Next, the Company must review the long-lived assets to define asset group(s) that would reflect the lowest level of assets to which discrete cash flows are identifiable. In performing this review, the Company identified that the long-lived asset “client relationships” related to Avelead should be classified as abandoned (the “Abandoned Asset”) with the Company determining that it no longer has plans to provide the corresponding consulting service. The Abandoned Asset’s carrying value would need to be set to its salvage value which would be zero given no future cash flows.

The Company determined the lowest level of discrete cash flows is at the reporting unit level, and all remaining long-lived assets (excluding the Abandoned Asset) and goodwill would represent its only asset group. Recoverability is assessed by comparing that the sum of the discrete undiscounted cash flows exceeds the carrying value of the asset group. The undiscounted cash flow projections are based on the primary asset in the asset group that include forecasts of future operating results based on internal budgets and strategic plans to investment in working capital to support anticipated revenue growth.

The undiscounted cash flows for the long-lived assets were above the carrying amounts indicating that the long-lived asset group is recoverable and no further impairment to long-lived assets exists as of October 31, 2023. For the three-month period ended October 31, 2023, the Company recorded $963,000 as “Impairment of long-lived assets” on its Condensed Consolidated Statement of Operations to adjust the Abandoned Asset to its salvage value of zero. There was no impairment to long-lived assets for the three-month period ending October 31, 2024.

Note 8 - Commitments and Contingencies

9 Months Ended

Oct. 31, 2024

Commitments and Contingencies Disclosure [Text Block]

NOTE 8 — COMMITMENTS AND CONTINGENCIES

Consulting Agreement with 180 Consulting, LLC

On March 19, 2020, the Company entered into a Master Services Agreement (the “MSA”) with 180 Consulting, pursuant to which 180 Consulting has provided and will continue to provide a variety of consulting services in support of eValuator products including product management, operational consulting, staff augmentation, internal systems platform integration and software engineering services, among others, through separate executed statements of work (“SOWs”). On September 20, 2021, the Company entered into a separate MSA in support of Avelead products. As of December 2023, all outstanding SOWs under both MSAs were effectively replaced by two new SOWs. As of October 31, 2024, there were three active SOWs under the eValuator MSA. One of the active SOWs includes the ability to earn stock at a conversion rate to be calculated 20 days after the execution of the related SOW. The MSA includes a termination clause upon a 90-day written notice. While no related party has a direct or indirect material interest in this MSA or the related SOWs, individuals providing services to the Company under the MSA and the SOWs may share workspace and administrative costs with 121G Consulting, LLC (“121G”). Mr. Green is a “member” of 121G, and, accordingly, has a financial interest in that entity. 180 Consulting earned 85,221 and 23,879 shares for the nine months ended October 31, 2024 and 2023, respectively, and has earned an aggregate of 183,875 shares of the Company’s common stock through October 31, 2024. For the three months ended October 31, 2024 and 2023, 180 Consulting earned 30,753 and 6,669 shares, respectively. For services rendered by 180 Consulting during the three and nine months ended October 31, 2024, the Company incurred fees of $642,000 and $1,965,000. The Company incurred fees of $639,000 and $2,558,000 for services rendered by 180 Consulting during the three and nine months ended October 31, 2023, respectively. For the three and nine months ended October 31, 2024, the Company recorded capitalized non-employee stock compensation of $41,000 and $109,000. The Company recorded capitalized non-employee stock compensation of $60,000 and $176,000, for the three and nine months ended October 31, 2023, respectively. The Company paid fees of $582,000 and $1,472,000 for services rendered by 180 Consulting during the three and nine months ended October 31, 2024, respectively. For the three and nine months ended October 31, 2023, the Company paid fees of $626,000 and $2,354,000, respectively, for services rendered by 180 Consulting.

Inclusive of the MSA executed with 180 Consulting are SOWs that provide for the Company to sublicense software through 180 Consulting that is owned by 121G. This is a services agreement for access to software that assists the Company in implementing and integrating with our clients’ technology. The license agreement is designed such that there is no material financial benefit that accrues to 121G. 180 Consulting licenses the software from 121G at cost. The Company paid approximately $230,000 and $453,000, and $87,000 and $468,000 for the SOWs that include the sublicense agreement for the three and nine months ended October 31, 2024 and 2023, respectively, which are included in the aforementioned totals above.

Litigation

We are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not aware of any legal matters that are reasonably possible to have a material adverse effect on the Company’s condensed consolidated results of operations, financial position or cash flows.

Note 5 - Debt - Schedule of Outstanding Debt (Details) - USD ($)	Oct. 31, 2024	Jan. 31, 2024
Total	$ 8,133,000	$ 9,066,000
Total	4,129,000	0
Less: Current portion of notes payable	0	0
Non-current portion of notes payable	4,129,000	0
Revolving Credit Facility [Member]
Long term debt, gross	177,000	135,000
Notes payable and accrued interest	177,000	135,000
Note Payable [Member[
Long term debt, gross	4,907,000	0
Less: Deferred financing cost	(136,000)	0
Notes payable and accrued interest	4,907,000	0
Less: Discount on notes payable	(642,000)	0
Term Loan [Member]
Long term debt, gross	8,000,000	9,000,000
Total	12,300,000
Less: Current portion of term loan	(2,250,000)	(1,500,000)
Total non-current portion of debt	5,883,000	7,566,000
Notes payable and accrued interest	8,000,000	9,000,000
Term Loan and Revolving Line of Credit [Member]
Less: Deferred financing cost	(44,000)	(69,000)
Less: Discount on notes payable	$ (179,000)	$ (193,000)

Note 8 - Commitments and Contingencies (Details Textual) - 180 Consulting [Member] - Master Services Agreement [Member] - USD ($)	3 Months Ended		9 Months Ended		55 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024
Stock Issued During Period, Shares, Issued for Services (in shares)	30,753	6,669	85,221	23,879	183,875
Professional Fees	$ 642,000	$ 639,000	$ 1,965,000	$ 2,558,000
Share-Based Payment Arrangement, Amount Capitalized	41,000	60,000	109,000	176,000
Payments for Other Fees	582,000	626,000	1,472,000	2,354,000
Statements of Work Under Sublease [Member]
Payments for Other Fees	$ 230,000	$ 87,000	$ 453,000	$ 468,000

Note 11 - Subsequent Events (Tables)

9 Months Ended

Oct. 31, 2024

Schedule of Debt, Adjusted EBITDA 1 [Table Text Block]

	Maximum
	ARR Net Leverage
Month Ending	Ratio
September 30, 2024		0.68 to 1.00
October 31, 2024		0.66 to 1.00
November 30, 2024		0.64 to 1.00
December 31, 2024		0.60 to 1.00
January 31, 2025		0.35 to 1.00
April 30, 2025		0.35 to 1.00

Schedule Of Minimum Adjusted EBITDA 1 [Table Text Block]

	Minimum
Month Ending	Adjusted EBITDA
September 30, 2024	$	(225,000	)
October 31, 2024		(500,000	)
November 30, 2024		(150,000	)
December 31, 2024		(100,000	)
January 31, 2025 and on the last day of each month thereafter through April 30, 2025		0

Note 2 - Summary of Significant Accounting Policies

9 Months Ended

Oct. 31, 2024